Investigational drug · Phase 2
rC19
Also called: Novavax's adjuvanted recombinant COVID-19
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19 Immunization, Influenza Immunization.
Phase 2Last checked: Nov 19, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
2
Any phase or sponsor naming "rC19"
First trial start
2024
Nov 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rC19", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19 Immunization
- Influenza Immunization
Approved drugs for the same conditions: COVID-19 · Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "rC19" as an intervention, largest first.
SanofiSanofi (SNY)
NCT06695130 · 980 participants · Start Nov 18, 2024 · Primary completion Apr 3, 2026
Drug: RIV (recombinant influenza vaccine); rC19 (dose 1) and 4 more · For: COVID-19 Immunization; Influenza Immunization
Sites: Phoenix, Arizona; Cerritos, California; Vista, California · 12 sites in all
SanofiSanofi (SNY)
NCT06695117 · 980 participants · Start Nov 19, 2024 · Primary completion Apr 16, 2026
Drug: IIV-HD; rC19 (dose 1) and 4 more · For: COVID-19 Immunization; Influenza Immunization
Sites: Birmingham, Alabama; Huntsville, Alabama; Tucson, Arizona · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Statistical analysis plan for the replacing protein via enteral nutrition in a stepwise approach in critically ill patients (REPLENISH) randomized clinical trial.
Arabi YM, Al-Dorzi HM, Aldibaasi O, et al. · Trials 2024
- Reduced Access to Preventive Care Due to the COVID-19 Pandemic, by Chronic Disease Status and Race and Hispanic Origin, United States, 2020-2021.
Irimata KE, Pleis JR, Heslin KC, et al. · Public Health Rep 2023
- Evaluation of the relative expression of genes associated with adherence after different hours of co-culture between Streptococcus uberis and MAC-T cells.
Fessia AS, Odierno LM · Microbes Infect 2022
- Relative expression of genes associated with adhesion to bovine mammary epithelial cells by Streptococcus uberis.
Fessia AS, Dieser SA, Renna MS, et al. · Res Vet Sci 2020
- Effects of plant growth promoting rhizobacteria (PGPR) on rooting and root growth of kiwifruit (Actinidia deliciosa) stem cuttings.
Erturk Y, Ercisli S, Haznedar A, et al. · Biol Res 2010
- Rapid modulation of synaptic plasticity by estrogens as well as endocrine disrupters in hippocampal neurons.
Ogiue-Ikeda M, Tanabe N, Mukai H, et al. · Brain Res Rev 2008
Also in development for COVID-19 Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.